Pesquisa | BVS Violência e Saúde

1.

Bictegravir/emtricitabine/tenofovir alafenamide in patients with genotypic NRTI resistance.

Shafran, Stephen D; Hughes, Christine A.

HIV Med ; 24(3): 361-365, 2023 03.

Artigo em Inglês | MEDLINE | ID: mdl-35973753

2.

Identifying gaps in the treatment of hepatitis C in patients co-infected with HIV in Edmonton, Alberta.

Round, Jessica M; Savaryn, Bohdan; Plitt, Sabrina S; Shafran, Stephen D; Charlton, Carmen L.

Ann Hepatol ; 23: 100283, 2021.

Artigo em Inglês | MEDLINE | ID: mdl-33217588

3.

Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts.

Mangia, Alessandra; Milligan, Scott; Khalili, Mandana; Fagiuoli, Stefano; Shafran, Stephen D; Carrat, Fabrice; Ouzan, Denis; Papatheodoridis, George; Ramji, Alnoor; Borgia, Sergio M; Wedemeyer, Heiner; Losappio, Ruggero; Pérez-Hernandez, Francisco; Wick, Nicole; Brown, Robert S; Lampertico, Pietro; Doucette, Karen; Ntalla, Ioanna; Ramroth, Heribert; Mertens, Michael; Vanstraelen, Kim; Turnes, Juan.

Liver Int ; 40(8): 1841-1852, 2020 08.

Artigo em Inglês | MEDLINE | ID: mdl-32449966

4.

Sofosbuvir/velpatasvir for 12â¯weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis.

Borgia, Sergio M; Dearden, Janet; Yoshida, Eric M; Shafran, Stephen D; Brown, Ashley; Ben-Ari, Ziv; Cramp, Matthew E; Cooper, Curtis; Foxton, Matthew; Rodriguez, Conrado Fernandez; Esteban, Rafael; Hyland, Robert; Lu, Sophia; Kirby, Brian J; Meng, Amy; Markova, Svetlana; Dvory-Sobol, Hadas; Osinusi, Anu O; Bruck, Rafael; Ampuero, Javier; Ryder, Stephen D; Agarwal, Kosh; Fox, Raymond; Shaw, David; Haider, Shariq; Willems, Bernard; Lurie, Yoav; Calleja, Jose Luis; Gane, Edward J.

J Hepatol ; 71(4): 660-665, 2019 10.

Artigo em Inglês | MEDLINE | ID: mdl-31195062

5.

Deferred treatment with a fixed-dose combination of sofosbuvir-velpatasvir for chronic hepatitis C virus genotype 1, 2, 4 and 6 infection.

Asselah, Tarik; Shafran, Stephen D; Bourgeois, Stefan; Lai, Ching-Lung; Mathurin, Philippe; Willems, Bernard; Nguyen, Mindie H; Davis, Mitchell N; Huang, K C; Svarovskaia, Evguenia; Osinusi, Anu; McNally, John; Brainard, Diana M; Shaikh, Obaid S; Tran, Tram T.

J Viral Hepat ; 26(10): 1229-1232, 2019 10.

Artigo em Inglês | MEDLINE | ID: mdl-31216086

6.

Identification of a Novel Hepatitis C Virus Genotype From Punjab, India: Expanding Classification of Hepatitis C Virus Into 8 Genotypes.

Borgia, Sergio M; Hedskog, Charlotte; Parhy, Bandita; Hyland, Robert H; Stamm, Luisa M; Brainard, Diana M; Subramanian, Mani G; McHutchison, John G; Mo, Hongmei; Svarovskaia, Evguenia; Shafran, Stephen D.

J Infect Dis ; 218(11): 1722-1729, 2018 10 20.

Artigo em Inglês | MEDLINE | ID: mdl-29982508

7.

Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies.

Hezode, Christophe; Reau, Nancy; Svarovskaia, Evguenia S; Doehle, Brian P; Shanmugam, Ragavi; Dvory-Sobol, Hadas; Hedskog, Charlotte; McNally, John; Osinusi, Anu; Brainard, Diana M; Miller, Michael D; Mo, Hongmei; Roberts, Stuart K; O'Leary, Jacqueline G; Shafran, Stephen D; Zeuzem, Stefan.

J Hepatol ; 68(5): 895-903, 2018 05.

Artigo em Inglês | MEDLINE | ID: mdl-29221887

8.

Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.

Feld, Jordan J; Jacobson, Ira M; Hézode, Christophe; Asselah, Tarik; Ruane, Peter J; Gruener, Norbert; Abergel, Armand; Mangia, Alessandra; Lai, Ching-Lung; Chan, Henry L Y; Mazzotta, Francesco; Moreno, Christophe; Yoshida, Eric; Shafran, Stephen D; Towner, William J; Tran, Tram T; McNally, John; Osinusi, Anu; Svarovskaia, Evguenia; Zhu, Yanni; Brainard, Diana M; McHutchison, John G; Agarwal, Kosh; Zeuzem, Stefan.

N Engl J Med ; 373(27): 2599-607, 2015 Dec 31.

Artigo em Inglês | MEDLINE | ID: mdl-26571066

9.

Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials.

Jacobson, Ira M; Lawitz, Eric; Gane, Edward J; Willems, Bernard E; Ruane, Peter J; Nahass, Ronald G; Borgia, Sergio M; Shafran, Stephen D; Workowski, Kimberly A; Pearlman, Brian; Hyland, Robert H; Stamm, Luisa M; Svarovskaia, Evguenia; Dvory-Sobol, Hadas; Zhu, Yanni; Subramanian, G Mani; Brainard, Diana M; McHutchison, John G; Bräu, Norbert; Berg, Thomas; Agarwal, Kosh; Bhandari, Bal Raj; Davis, Mitchell; Feld, Jordan J; Dore, Gregory J; Stedman, Catherine A M; Thompson, Alexander J; Asselah, Tarik; Roberts, Stuart K; Foster, Graham R.

Gastroenterology ; 153(1): 113-122, 2017 07.

Artigo em Inglês | MEDLINE | ID: mdl-28390869

10.

Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study.

Feld, Jordan J; Ramji, Alnoor; Shafran, Stephen D; Willems, Bernard; Marotta, Paul; Huchet, Emmanuelle; Vachon, Marie-Louise; Svarovskaia, Evguenia S; Huang, K C; Hyland, Robert H; Yun, Chohee; Massetto, Benedetta; Brainard, Diana M; McHutchison, John G; Tam, Edward; Bailey, Robert; Cooper, Curtis; Yoshida, Eric M; Greenbloom, Susan; Elkhashab, Magdy; Borgia, Sergio; Swain, Mark G.

Clin Infect Dis ; 65(1): 13-19, 2017 Jul 01.

Artigo em Inglês | MEDLINE | ID: mdl-28535298

11.

Reply to: "Real-world experience of serial serum levels of GS-331007 in chronic hepatitis C hemodialysis patients during and after sofosbuvir/velpatasvir therapy".

Borgia, Sergio M; Shafran, Stephen D.

J Hepatol ; 75(4): 1007-1008, 2021 10.

Artigo em Inglês | MEDLINE | ID: mdl-34293344

12.

Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection.

Dore, Gregory J; Lawitz, Eric; Hézode, Christophe; Shafran, Stephen D; Ramji, Alnoor; Tatum, Harvey A; Taliani, Gloria; Tran, Albert; Brunetto, Maurizia R; Zaltron, Serena; Strasser, Simone I; Weis, Nina; Ghesquiere, Wayne; Lee, Samuel S; Larrey, Dominique; Pol, Stanislas; Harley, Hugh; George, Jacob; Fung, Scott K; de Lédinghen, Victor; Hagens, Peggy; McPhee, Fiona; Hernandez, Dennis; Cohen, David; Cooney, Elizabeth; Noviello, Stephanie; Hughes, Eric A.

Gastroenterology ; 148(2): 355-366.e1, 2015 Feb.

Artigo em Inglês | MEDLINE | ID: mdl-25311593

13.

Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study.

Hézode, Christophe; Hirschfield, Gideon M; Ghesquiere, Wayne; Sievert, William; Rodriguez-Torres, Maribel; Shafran, Stephen D; Thuluvath, Paul J; Tatum, Harvey A; Waked, Imam; Esmat, Gamal; Lawitz, Eric J; Rustgi, Vinod K; Pol, Stanislas; Weis, Nina; Pockros, Paul J; Bourlière, Marc; Serfaty, Lawrence; Vierling, John M; Fried, Michael W; Weiland, Ola; Brunetto, Maurizia R; Everson, Gregory T; Zeuzem, Stefan; Kwo, Paul Y; Sulkowski, Mark; Bräu, Norbert; Hernandez, Dennis; McPhee, Fiona; Wind-Rotolo, Megan; Liu, Zhaohui; Noviello, Stephanie; Hughes, Eric A; Yin, Philip D; Schnittman, Steven.

Gut ; 64(6): 948-56, 2015 Jun.

Artigo em Inglês | MEDLINE | ID: mdl-25080450

14.

HIV Coinfected Have Similar SVR Rates as HCV Monoinfected With DAAs: It's Time to End Segregation and Integrate HIV Patients Into HCV Trials.

Shafran, Stephen D.

Clin Infect Dis ; 61(7): 1127-34, 2015 Oct 01.

Artigo em Inglês | MEDLINE | ID: mdl-26060286

15.

Prevention of Shingles: Better Protection and Better Value With Recombinant Vaccine.

Shafran, Stephen D.

Ann Intern Med ; 170(6): 416-417, 2019 03 19.

Artigo em Inglês | MEDLINE | ID: mdl-30776802

16.

Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial.

Sulkowski, Mark S; Bourlière, Marc; Bronowicki, Jean-Pierre; Asselah, Tarik; Pawlotsky, Jean-Michel; Shafran, Stephen D; Pol, Stanislas; Mauss, Stefan; Larrey, Dominique; Datsenko, Yakov; Stern, Jerry O; Kukolj, George; Scherer, Joseph; Nehmiz, Gerhard; Steinmann, Gerhard G; Böcher, Wulf O.

Hepatology ; 57(6): 2155-63, 2013 Jun.

Artigo em Inglês | MEDLINE | ID: mdl-23504636

17.

Reply to Menard et al.

Shafran, Stephen D.

Clin Infect Dis ; 62(7): 949-50, 2016 Apr 01.

Artigo em Inglês | MEDLINE | ID: mdl-26740516

18.

Hepatitis C direct-acting antiviral outcomes in patients 75 years and older.

Parmar, Parmvir; Shafran, Stephen D; Borgia, Sergio M; Doucette, Karen; Cooper, Curtis L.

JGH Open ; 5(2): 253-257, 2021 Feb.

Artigo em Inglês | MEDLINE | ID: mdl-33553664

19.

Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.

Shiffman, Mitchell L; Suter, Fredy; Bacon, Bruce R; Nelson, David; Harley, Hugh; Solá, Ricard; Shafran, Stephen D; Barange, Karl; Lin, Amy; Soman, Ash; Zeuzem, Stefan.

N Engl J Med ; 357(2): 124-34, 2007 Jul 12.

Artigo em Inglês | MEDLINE | ID: mdl-17625124

20.

Challenges in initiating antiretroviral therapy in 2010.

Tremblay, Cécile L; Baril, Jean-Guy; Fletcher, David; Kilby, Donald; Macpherson, Paul; Shafran, Stephen D; Tyndall, Mark W.

Can J Infect Dis Med Microbiol ; 21 Suppl C: 1C-15C, 2010 Aug.

Artigo em Inglês | MEDLINE | ID: mdl-23365594

BVS Violência e Saúde

Informação e Conhecimento para a Saúde

Configurar filtros

Sua seleção (0)

Formato de exportação:

Exportar:

Bictegravir/emtricitabine/tenofovir alafenamide in patients with genotypic NRTI resistance.

Identifying gaps in the treatment of hepatitis C in patients co-infected with HIV in Edmonton, Alberta.

Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts.

Sofosbuvir/velpatasvir for 12â¯weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis.

Deferred treatment with a fixed-dose combination of sofosbuvir-velpatasvir for chronic hepatitis C virus genotype 1, 2, 4 and 6 infection.

Identification of a Novel Hepatitis C Virus Genotype From Punjab, India: Expanding Classification of Hepatitis C Virus Into 8 Genotypes.

Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies.

Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.

Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials.

Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study.

Reply to: "Real-world experience of serial serum levels of GS-331007 in chronic hepatitis C hemodialysis patients during and after sofosbuvir/velpatasvir therapy".

Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection.

Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study.

HIV Coinfected Have Similar SVR Rates as HCV Monoinfected With DAAs: It's Time to End Segregation and Integrate HIV Patients Into HCV Trials.

Prevention of Shingles: Better Protection and Better Value With Recombinant Vaccine.

Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial.

Reply to Menard et al.

Hepatitis C direct-acting antiviral outcomes in patients 75 years and older.

Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.

Challenges in initiating antiretroviral therapy in 2010.